Scarica l'app Stockscreener
23.10
4.90%
-1.19
Dopo l'orario di chiusura:
22.50
-0.60
-2.60%
Precedente Chiudi:
$24.29
Aprire:
$23.5
Volume 24 ore:
692.17K
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.07B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
15.93
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
-7.27%
1M Prestazione:
-1.83%
6M Prestazione:
+39.87%
1 anno Prestazione:
-18.66%
Intervallo 1D:
$22.63
$24.03
Intervallo di 1 settimana:
$22.63
$25.20
Portata 52W:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
813-553-6680
Indirizzo
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.10 | 1.07B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
151.73 | 67.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 46.50B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.89 | 44.66B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.80 | 15.81B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.46 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - markets.businessinsider.com
Pacira launches Phase 2 osteoarthritis gene therapy trial - Investing.com
Pacira BioSciences Announces First Patient Dosed in Phase 2 - GlobeNewswire
Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee - MarketScreener
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and ... - Bluefield Daily Telegraph
Game-Changing Knee Osteoarthritis Gene Therapy Advances After 2-Year Pain Relief Success - Stock Titan
Shareholders that lost money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Teacher Retirement System of Texas Acquires 2,034 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
(PCRX) Technical Data - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Leading Pain Therapy Innovator Pacira Set for Major Investor Presentation at Needham Conference - Stock Titan
Pacira Just Misses Meeting Wall Street’s 2024 Expectations - Orthopedics This Week
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Investors to Inquire about Securities Investigation - markets.businessinsider.com
PNC Financial Services Group Inc. Has $68,000 Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out - Markets Insider
Pacira BioSciences Inc (PCRX) Shares Gap Down to $23.97 on Mar 2 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out - Markets Insider
What is Zacks Research’s Estimate for PCRX FY2027 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Connect - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Pacira Surges 66.8% in Six Months: How Should You Play the Stock? - Zacks Investment Research
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Commit To Buy Pacira BioSciences At $20, Earn 14.4% Annualized Using Options - Nasdaq
Chronic Pain Market Growth Projections 2024-2034: DelveInsight Analysis | Pacira BioSciences, Paradigm Biopharma, Tonix Pharma - The Globe and Mail
Victory Capital Management Inc. Sells 27,478 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
DOMA Perpetual’s Nomination of Three Highly Qualified Candidates for the Board of Pacira BioSciences - Global Legal Chronicle
Bank of New York Mellon Corp Has $7.47 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $27.22 - Armenian Reporter
Pacira BioSciences: Back On An Uptrend After Positive Developments (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences adopts majority vote standard for director elections By Investing.com - Investing.com Australia
Pacira BioSciences adopts majority vote standard for director elections - Investing.com
Pacira evaluates DOMA board nominees amid growth plans By Investing.com - Investing.com South Africa
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual -March 14, 2025 at 04:13 pm EDT - Marketscreener.com
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual - GlobeNewswire
Pacira Faces Board Challenge as Activist DOMA Pushes for Change Despite New Growth Plan - StockTitan
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences - Morningstar
Class Action Filed Against Pacira BioSciences, Inc. (PCRX)March 14, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. ... - Bluefield Daily Telegraph
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX - GlobeNewswire Inc.
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Pacira BioSciences, Inc. Securities Fraud Class Action - GlobeNewswire
The Gross Law Firm Reminds Pacira BioSciences, Inc. Investors of - GuruFocus.com
Pacira BioSciences, Inc. Investors: Please contact the - GlobeNewswire
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & ... - Bluefield Daily Telegraph
FINAL REMINDER PCRX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Pacira BioSciences, Inc. Investors to Participate in the Class Action Lawsuit - Markets Insider
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $27.22 - Defense World
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):